Innovent Biologics announces positive Phase 2 results for Efdamrofusp Alfa in nAMD
In an important development for the treatment of neovascular age-related macular degeneration (nAMD), Innovent Biologics, Inc., a leading biopharmaceutical company, has announced successful results from ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related ... Read More
Novartis to acquire ocular gene therapy company Gyroscope Therapeutics
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up to $1.5 billion. As per the terms ... Read More
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy, a severe form of age-related macular degeneration ... Read More
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the ... Read More
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu ... Read More